tetano
Editor, Senior Moderator
Clin Cardiol
. 2024 Feb;47(2):e24240.
doi: 10.1002/clc.24240. The incidence and impact of atrial fibrillation on hospitalized Coronavirus disease-2019 patients
Haiming Niu[SUP] 1 [/SUP], Jianwei Li[SUP] 1 [/SUP], Catherine Teng[SUP] 2 [/SUP], Xiaojia Lu[SUP] 3 [/SUP], Chengyue Jin[SUP] 4 [/SUP], Peng Cai[SUP] 5 [/SUP], Ao Shi[SUP] 6 [/SUP], Xiaoqing Shen[SUP] 1 [/SUP], Qiqi Chen[SUP] 1 [/SUP], Miaolian Chen[SUP] 1 [/SUP], Yong Yuan[SUP] 7 [/SUP], Pengyang Li[SUP] 8 [/SUP]
Affiliations
Background: Since 2019, Coronavirus disease-2019 (COVID-19) has raised unprecedented global health crisis. The incidence and impact of atrial fibrillation (AF) on patients with COVID-19 remain unclearly defined.
Methods: We conducted a retrospective cohort study using ICD-10 codes to identify patients with a primary diagnosis of COVID-19 with or without AF in National Inpatient Sample Database 2020. We compared the outcome of COVID-19 patients with a concurrent diagnosis of AF with those without.
Hypothesis: AF will adversely affect the prognosis of hospitalized COVID-19 patients.
Results: A total of 211 619 patients with a primary diagnosis of COVID-19 were identified. Among these patients, 31 923 (15.08%) had a secondary diagnosis of AF. Before propensity score matching, COVID-AF cohort was older (75.8 vs. 62.2-year-old, p < .001) and had more men (57.5% vs. 52.0%, p < .001). It is associated with more comorbidities, mainly including diabetes mellitus (43.7% vs. 39.9%, p < .001), hyperlipidemia (54.6% vs. 39.8%, p < .001), chronic kidney disease (34.5% vs. 17.0%, p < .001), coronary artery disease (35.3% vs. 14.4%, p < .001), anemia (27.8% vs. 18.6%, p < .001), and cancer (4.8% vs. 3.4%, p < .001). After performing propensity score match, a total of 31 862 patients were matched within each group. COVID-AF cohort had higher inpatient mortality (22.2% vs. 15.3%, p < .001) and more complications, mainly including cardiac arrest (3.9% vs. 2.3%, p < .001), cardiogenic shock (0.9% vs. 0.3%, p < .001), hemorrhagic stroke (0.4% vs. 0.3%, p = .025), and ischemic stroke (1.3% vs. 0.7%, p < .001). COVID-AF cohort was more costly, with a longer length of stay, and a higher total charge.
Conclusion: AF is common in patients hospitalized for COVID-19, and is associated with poorer in-hospital mortality, immediate complications and increased healthcare resource utilization.
Keywords: COVID-19; atrial fibrillation; in-hospital complication; mortality.
. 2024 Feb;47(2):e24240.
doi: 10.1002/clc.24240. The incidence and impact of atrial fibrillation on hospitalized Coronavirus disease-2019 patients
Haiming Niu[SUP] 1 [/SUP], Jianwei Li[SUP] 1 [/SUP], Catherine Teng[SUP] 2 [/SUP], Xiaojia Lu[SUP] 3 [/SUP], Chengyue Jin[SUP] 4 [/SUP], Peng Cai[SUP] 5 [/SUP], Ao Shi[SUP] 6 [/SUP], Xiaoqing Shen[SUP] 1 [/SUP], Qiqi Chen[SUP] 1 [/SUP], Miaolian Chen[SUP] 1 [/SUP], Yong Yuan[SUP] 7 [/SUP], Pengyang Li[SUP] 8 [/SUP]
Affiliations
- PMID: 38402574
- PMCID: PMC10894524
- DOI: 10.1002/clc.24240
Background: Since 2019, Coronavirus disease-2019 (COVID-19) has raised unprecedented global health crisis. The incidence and impact of atrial fibrillation (AF) on patients with COVID-19 remain unclearly defined.
Methods: We conducted a retrospective cohort study using ICD-10 codes to identify patients with a primary diagnosis of COVID-19 with or without AF in National Inpatient Sample Database 2020. We compared the outcome of COVID-19 patients with a concurrent diagnosis of AF with those without.
Hypothesis: AF will adversely affect the prognosis of hospitalized COVID-19 patients.
Results: A total of 211 619 patients with a primary diagnosis of COVID-19 were identified. Among these patients, 31 923 (15.08%) had a secondary diagnosis of AF. Before propensity score matching, COVID-AF cohort was older (75.8 vs. 62.2-year-old, p < .001) and had more men (57.5% vs. 52.0%, p < .001). It is associated with more comorbidities, mainly including diabetes mellitus (43.7% vs. 39.9%, p < .001), hyperlipidemia (54.6% vs. 39.8%, p < .001), chronic kidney disease (34.5% vs. 17.0%, p < .001), coronary artery disease (35.3% vs. 14.4%, p < .001), anemia (27.8% vs. 18.6%, p < .001), and cancer (4.8% vs. 3.4%, p < .001). After performing propensity score match, a total of 31 862 patients were matched within each group. COVID-AF cohort had higher inpatient mortality (22.2% vs. 15.3%, p < .001) and more complications, mainly including cardiac arrest (3.9% vs. 2.3%, p < .001), cardiogenic shock (0.9% vs. 0.3%, p < .001), hemorrhagic stroke (0.4% vs. 0.3%, p = .025), and ischemic stroke (1.3% vs. 0.7%, p < .001). COVID-AF cohort was more costly, with a longer length of stay, and a higher total charge.
Conclusion: AF is common in patients hospitalized for COVID-19, and is associated with poorer in-hospital mortality, immediate complications and increased healthcare resource utilization.
Keywords: COVID-19; atrial fibrillation; in-hospital complication; mortality.